About Us

Overview

3DBio Therapeutics is a biologics and bioprinting company with a focus on regenerative medicine that precision manufactures living tissues to allow replacement of each individual patient’s parts with tissues designed and created specifically for them. 3DBio has developed unique capabilities toward the creation of living tissue implants for therapeutic applications. The technology platforms include a full suite of features to meet the FDA’s requirements for therapeutic manufacturing, including novel and proprietary: 3D-bioprinter (GMPrint™), bio-ink (ColVivo™), and cell processes. In pre-clinical studies the platform has demonstrated the ability to generate functioning living tissues.

Management & Co-Founders

Daniel Cohen, Ph.D. — Chief Executive Officer & Co-Founder

Daniel Cohen, Ph.D., is the CEO and Co-founder of 3DBio Therapeutics. Prior to 3DBio, Daniel was an Engagement Manager at McKinsey & Company in New York, where he focused on manufacturing, industrials, healthcare, and 3D printing. He received his Ph.D., as well as B.S. and M.S. degrees, in Mechanical Engineering from Cornell University, with minors in Biomedical and Electrical Engineering. Dr. Cohen was awarded both the National Science Foundation Graduate Research Fellowship, and the Department of Homeland Security Graduate Fellowship. At Cornell, he focused on bioprinting technology, completing his doctoral dissertation on 3D printing & bioprinting and holds numerous publications and patents in the field.

Harlan Weisman, M.D. — Executive Chairman

Harlan F. Weisman, M.D., is the Executive Chairman of 3DBio Therapeutics. He was formerly the Chief Science and Technology Officer for Medical Devices and Diagnostics at Johnson & Johnson. Prior, Dr. Weisman held the position of Company Group Chairman, Research & Development for Pharmaceuticals. Dr. Weisman joined J&J from Centocor, where he was the President of Research & Development. Harlan was also an Assistant Professor of Medicine and Consultant Cardiologist at Johns Hopkins University School of Medicine. Dr. Weisman received his B.A. in Philosophy from the University of Maryland and his M.D. from the University of Maryland School of Medicine.

Nathaniel Bachrach, Ph.D. — Chief Scientific Officer & Executive Vice President

Nathaniel Bachrach, Ph.D., is Chief Scientific Officer and Executive Vice President of 3DBio Therapeutics. Prior to 3DBio, Nathaniel was the Vice President of Research & Technology at LifeCell (NASDAQ: LIFC), which was acquired by Allergan. Nathaniel came to LifeCell from Organogenesis. Dr. Bachrach received his Ph.D., as well as B.S. and M.S. degrees, in Mechanical Engineering from Columbia University in New York, where his research focused on cartilage and regenerative medicine.

Larry Bonassar, Ph.D. — Co-Founder

Larry Bonassar, Ph.D., is a Co-Founder of 3DBio. Larry is the Daljit S. and Elaine Sarkaria Professor of Biomedical Engineering, and holds dual appointments in the Departments of Biomedical and Mechanical Engineering. He is on the Board of Directors of both the International Society for Biofabrication, and the Orthopaedic Research Society. Dr. Bonassar completed postdoctoral fellowships in the Orthopaedic Research Laboratory at the Massachusetts General Hospital and in the Center for Biomedical Engineering at the Massachusetts Institute of Technology. Larry has a received his Ph.D. and M.S. in materials science and engineering from MIT, and his B.S. from Johns Hopkins University.

Hod Lipson, Ph.D. — Co-Founder

Hod Lipson, Ph.D., is a Co-Founder of 3DBio. Hod is a Professor of Mechanical Engineering and Data Science at Columbia University in New York. Before joining Columbia University in 2015, Hod spent 14 years as a professor at Cornell University. Dr. Lipson’s work includes the development of seminal aspects of 3D printing with non-traditional materials. Hod is the co-author of the award winning book “Fabricated: The New World of 3D printing” and has published over 300 scholarly articles. Dr. Lipson received his Ph.D. in 1999 from the Technion – Israel Institute of Technology, followed by a postdoc at Brandeis University and MIT.

Board of Directors

Harlan Weisman, M.D. — Executive Chairman

Harlan F. Weisman, M.D., was Chief Science and Technology Officer for Medical Devices and Diagnostics at Johnson & Johnson. Prior, Dr. Weisman held the position of Company Group Chairman, Research & Development for Pharmaceuticals. Dr. Weisman joined J&J from Centocor, where he was the President of Research & Development. Harlan was also an Assistant Professor of Medicine and Consultant Cardiologist at Johns Hopkins University School of Medicine. Dr. Weisman received his B.A. in Philosophy from the University of Maryland and his M.D. from the University of Maryland School of Medicine.

Daniel Cohen, Ph.D. — Chief Executive Officer & Co-Founder

Daniel Cohen, Ph.D., is the CEO and Co-founder of 3DBio Therapeutics. Prior to 3DBio, Daniel was an Engagement Manager at McKinsey & Company in New York, where he focused on manufacturing, industrials, healthcare, and 3D printing. He received his Ph.D., as well as B.S. and M.S. degrees, in Mechanical Engineering from Cornell University, with minors in Biomedical and Electrical Engineering. Dr. Cohen was awarded both the National Science Foundation Graduate Research Fellowship, and the Department of Homeland Security Graduate Fellowship. At Cornell, he focused on bioprinting technology, completing his doctoral dissertation on 3D printing & bioprinting and holds numerous publications and patents in the field.

Sol Barer, Ph.D.

Michael Bator, MBA

Michael G. Bator is the founder of Certus Advisory. Mr. Bator previously was Chief Financial Officer for Trek Therapeutics, Consultant at The Boston Consulting Group, Managing Director at Healthcare Research Systems, and Managing Director at Jennison Associates. Michael G. Bator received an undergraduate degree from Princeton University and an MBA from The Wharton School of the University of Pennsylvania.

Kevin Slawin, M.D.

Kevin Slawin, MD., is the Founder and Managing Partner of Rapha Capital Management, LLC.  He is a successful and experienced oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on breakthrough healthcare technologies.  He is the founder of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) and the Vanguard Urologic Institute at Memorial Hermann Medical Group in Houston, Texas, where he was also the Director of Urology at Memorial Hermann Hospital. Slawin graduated, magna cum laude, with a Bachelor of Arts degree in Biochemistry from Columbia University, and earned his medical degree in 1986 from Columbia College of Physicians and Surgeons, and was elected to the Alpha Omega Alpha honor society.